In addition, our present results also confirmed that HER2-positive or triple-negative subtype had significantly greater odds of developing liver metastases than HR+/HER2- subtype, consistent with previously published studies focused on the metastatic pattern of different breast cancer subtype [10, 19, 20, 22]. This evidence concerns the gene ERBB2 and breast cancer.